Dosing strategies for anticancer drugs: The good, the bad and body-surface area

European Journal of Cancer

Volumn 38, Issue 13, 2002, Pages 1677-1684

  Felici, A ^b   Verweij, J ^b   Sparreboom, A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Anticancer drugs; Body surface area; Dosing strategies; Pharmacokinetics

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; BUSULFAN; CAPACITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; PACLITAXEL; PLEVITREXED; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG;

BODY SURFACE; CANCER CHEMOTHERAPY; DOSIMETRY; DRUG CLEARANCE; DRUG EFFECT; HUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; DOSE RESPONSE; METABOLISM; NEOPLASM;

ANTINEOPLASTIC AGENTS; BODY SURFACE AREA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEOPLASMS;

EID: 0036024583     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00151-X     Document Type: Article

References (56)

1. A formula to estimate the approximate surface area if height and weight be known
2. Estimation of human body surface area from height and weight
3. Comparison of the Du Bois formula with direct photometric measurement
4. Lean body mass as a predictor of drug dosage
5. The impact of obesity and disease on busulfan oral clearance in adults
6. The use of surface area for establishing normal blood volume
7. Body size and metabolism
8. Poor correlation between body surface area and glomerular filtration rate
9. The use of body surface area as a criterion of drug dosage in cancer chemotherapy
10. Is the dose normalization to weight and body surface area useful in adults?
11. Randomised-crossover evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel
12. Gemcitabine pharmacokinetics are influenced by gender, body surface area (BSA), and duration of infusion
13. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil
14. Impact of body-size measures on irinotecan clearance: Alternative dosing recommendations
15. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure
16. Inter- and intra-patient variability in oral topotecan pharmacokinetics: Implications for body-surface area dosage regimens
17. Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation
18. What is the effect of adjusting epirubicin doses for body surface area?
19. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: Results of a multicenter study
20. Bioequivalence of two methotrexate formulations in psoriatic and cancer patients
21. Relative importance of dose, body surface area, sex and age for 5-fluorouracil clearance
22. Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative
23. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis
24. A population pharmacokinetic model for docetaxel (Taxotere): Model building and validation
25. Pharmacokinetic and pharmacodynamic properties of docetaxel: Results of phase I and phase II trials
26. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationship for docetaxel
27. Phase I and II clinical trials of Trastuzumab
28. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations
29. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
30. A phase I and pharmacological study of intermittent dosing of PKI166, a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administered orally to patients with advanced cancer
31. Long-term pharmacokinetics of doxorubicin HCI stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP)
32. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
33. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer
34. Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies
35. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
36. Overview of recent topics in clinical pharmacology of anticancer agents
37. The effect of individual's Cytochrome CYP3A4 activity on docetaxel clearance
38. Correlation between docetaxel clearance and estimate cytochrome P450 activity by urinary metabolite of exogenous cortisol
39. Randomized pharmacokinetic (PK) and pharmacodynamic (PD) study of docetaxel: Fixed-dose (FIX) versus individualized-dose (IND) based on cytochrome P450 (CYP3A4) activity estimated from urinary metabolite of exogenous cortisol
40. Individualizing dosing of cancer chemotherapy
41. Familiar deficiency of Biochemical basis for familiar pyrimidinemia and severe 5-fluorouracil-induced toxicity
42. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A potentially more common pharmacogenetic syndrome
43. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
44. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment
45. Therapeutic drug monitoring of cytotoxic drugs
46. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
47. Pharmacologically based dosing of etoposide: A means of safety increasing dose intensity
48. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research compaign phase I/II commettee study
49. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer
50. Can pharmacokinetic monitoring improve clinical use of fluorouracil?
51. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: Results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients
52. Bioequivalence of two tablet formulations of capacitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients
53. Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients
54. Population pharmacokinetics of total unbound etoposide
55. Population pharmacokinetics of temozolomide in cancer patients